(Q37800039)

23 August 2017

title

"Overcoming breast cancer drug resistance with mTOR inhibitors". Could it be a myth or a real possibility in the short-term future? (English)

1 reference

23 August 2017

1 reference

2

1 reference

23 August 2017

Nadia Margariti

1

1 reference

23 August 2017

Alberto Bottini

series ordinal

3

1 reference

23 August 2017

Daniele Generali

series ordinal

4

1 reference

23 August 2017

language of work or name

English

0 references

publication date

14 October 2010

1 reference

Breast Cancer Research and Treatment

23 August 2017

published in

1 reference

23 August 2017

volume

128

1 reference

23 August 2017

issue

3

1 reference

23 August 2017

page(s)

599-606

1 reference

Clinical pharmacokinetics of everolimus

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0986-9

Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0986-9

Farnesylthiosalicylic acid blocks mammalian target of rapamycin signaling in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0986-9

Endocrine-responsive breast cancer and strategies for combating resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0986-9

Mechanisms of acquired resistance to endocrine therapy in hormone-dependent breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0986-9

Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0986-9

Biological determinants of endocrine resistance in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0986-9

Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0986-9

Effects of a combined treatment with mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0986-9

Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0986-9

Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0986-9

S6 kinase 1 regulates estrogen receptor alpha in control of breast cancer cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0986-9

Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0986-9

Down-regulation of phosphatidylinositol 3'-kinase/AKT/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0986-9

Phosphorylated ERalpha, HIF-1alpha, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0986-9

Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0986-9

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0986-9

Targeted therapies in breast cancer: where are we now?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0986-9

Antiestrogen-resistant human breast cancer cells require activated protein kinase B/Akt for growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0986-9

Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0986-9

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0986-9

Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0986-9

Elevated expression of mitogen-activated protein kinase phosphatase 3 in breast tumors: a mechanism of tamoxifen resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0986-9

Epidermal growth factor receptor pathway analysis identifies amphiregulin as a key factor for cisplatin resistance of human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0986-9

ERK phosphorylation is linked to VEGFR2 expression and Ets-2 phosphorylation in breast cancer and is associated with tamoxifen treatment resistance and small tumours with good prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0986-9

Circulating concentrations of insulin-like growth factor I and risk of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-0986-9

10.1007/S10549-010-0986-9

21 January 2018

Identifiers

DOI

1 reference

23 August 2017

1 reference